Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Item

http://www.wikidata.org/entity/Q37360526

Q37360526

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection H2-Mbeta 1 and H2-Mbeta 2 heterodimers equally promote clip removal in I-A(q) molecules from autoimmune-prone DBA/1 mice TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis.High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients.Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors.T-cell recognition of melanoma-associated antigens.Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.Immune selection in neoplasia: towards a microevolutionary model of cancer development.Strategies to overcome obstacles to successful immunotherapy of melanoma Trends in cancer immunotherapy Modeling putative therapeutic implications of exosome exchange between tumor and immune cells.Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance.Peptide vaccines for cancer.Therapeutic vaccination with tumor cells that engage CD137.CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas Cell surface expression level variation between two common Human Leukocyte Antigen alleles, HLA-A2 and HLA-B8, is dependent on the structure of the C terminal part of the alpha 2 and the alpha 3 domains.Challenges and future perspectives of T cell immunotherapy in cancer Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.Vaccination: role in metastatic melanoma.Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.Specificity in cancer immunotherapy.Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.Multipeptide vaccination in cancer patients.Improving T cell responses to modified peptides in tumor vaccines Influence of immune privilege on ocular tumor development.The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.Lessons from cancer immunoediting in cutaneous melanoma.Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.Immunotherapeutic approaches for cancer therapy: An updated review.Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression.

P2860

Q21131200-ED896DB0-89FE-4D87-92E5-36DF57340C72 Q24674180-B1F97AFB-9DF4-44BA-A604-0F1510483AD6 Q24814910-6659A2A5-8BA6-4C37-9BD0-F131C4C77035 Q27023313-427D5ECC-F0FD-47A9-82CA-21E8DB4B6A28 Q27680531-4F42CFF9-6D4D-452C-9D45-FC5266EDD2A9 Q28585977-86569921-5C17-44C6-8EC8-157DD096C58C Q32159956-7B809C56-16C5-480E-95D4-25080F3B7F14 Q33432819-D09F4156-2BCB-4603-B64B-B411C7FCEA07 Q33598281-57BA505E-467A-4190-AE3C-E29F97D00127 Q33827458-7C45844D-855A-4AC1-912A-63879D713B72 Q33911899-D3DADEC0-DE5A-4A95-880F-0B7D2D2F2199 Q33931006-8B43836E-0498-4C69-AD84-268EF397DBD5 Q33948688-DAD4DF95-32BE-45E2-B7AB-5CA63B13FD05 Q34042968-31247592-040D-4CBF-948A-8BDF1AD0B926 Q34052702-8B609D4C-C3DB-47F6-B5AA-EC222A4E80DE Q34407541-32B12EA5-5C05-4AAD-B225-F46107E2A703 Q34415738-65D81851-77F8-437A-AF45-182EFFA690EA Q34452013-F7877DD3-25E0-4694-98D5-3DBB01F7B179 Q34568992-1981C8D9-48AE-4FC3-A78E-2F42F8B215BA Q35071688-4548888C-0199-43AB-955F-01E25DB8C2F2 Q35228053-B9ECD2B1-63A6-4CFD-A10C-74EE646BD0AA Q35507485-27C60419-B052-4595-AFE0-80A704B4AB03 Q35741278-F471F57A-B5D5-4A63-83BB-D8283E126A8D Q35843507-01313792-F1A9-4018-BF4C-C16E0C5DBEAE Q35886748-CFC19A3D-44A0-4F7A-B63E-2FE9D9749085 Q36476449-EF477201-22AB-4439-AEFF-7825FF8E6C4F Q36509702-E5FA0046-FBD5-42D7-BE1F-1305DB9551AF Q36573868-2A1B5119-18C6-416E-865F-0474DAB6ACE1 Q37047061-45A27395-6DF2-4CAF-8E67-50481C41C42D Q37066149-201DDEBA-1046-4EE0-B01F-35A88CBDAE39 Q37236636-26F2BBCA-C8C5-488A-B261-3FFBEDB40A8A Q37328301-26161443-959A-42B5-B737-24EA037E51AD Q37547268-86F164C7-7B58-4A38-943A-E1F5CB057DB2 Q37634253-1AF8EBB4-F375-48A5-98D3-29C3F624108E Q37724789-A4455855-B918-4D08-AB37-76CF97FD8800 Q38021845-51809F8B-1B9F-4E6C-A66F-AB02185BF20B Q38038176-1C928B29-19E3-471D-9AAD-9B428318A5DC Q38088635-0F06139E-631B-4D35-84AB-8CB262A492E6 Q38388102-CA8248A6-9BFC-4DB6-B67F-C39FE4C62676 Q39094369-C8252536-1C24-43D7-94DE-3D8ECC67F8D2

P2860

Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Item

http://www.wikidata.org/entity/Q37360526

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 1996

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs